+ New Watchlist

Benzinga Research

-

-

-

-

-

-

-

Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise

Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Government
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs

Free Benzinga Pro Trial

Calendars

Analyst Ratings Calendar

Conference Call Calendar

Dividend Calendar

Earnings Calendar

Economic Calendar

Guidance Calendar

Stock Split Calendar

Trade Ideas

Free Stock Reports

Trade Idea Feed

Analyst Ratings

Unusual Options Activity

Free Newsletter

Government Trades

Short Interest

Largest Increase

Largest Decrease

Calculators

Margin Calculator

Forex Profit Calculator

100x Options Profit Calculator

-

-

-

-

-

-

-

Apellis Pharmaceuticals

APLSNASDAQ

Perks Buy Compare Brokers

$36.24

0.832.34%

At Close: -

$36.24

00.00%

After Hours: Jul 5, 4:00 PM EDT

15 minutes delayed

Apellis Pharmaceuticals (APLS) Forecast

News

Earnings Guidance Dividends Analyst Ratings Insider Trades Short Interest

Latest news for Apellis Pharmaceuticals (NASDAQ:APLS) Stock

Apellis Pharmaceuticals Stock (NASDAQ: APLS)

Categories: All

All News

General

Contracts

Dividends

Events

FDA

M&A

Offerings

Stock Split

Media

Buybacks

Insider Trades

Earnings

Guidance

Analyst Ratings

Trading Ideas

All News

General

Contracts

Dividends

Events

FDA

M&A

Offerings

Stock Split

Media

Buybacks

Insider Trades

Earnings

Guidance

Analyst Ratings

Trading Ideas

Friday, June 28, 2024

What Analysts Are Saying About Apellis Pharmaceuticals Stock
Benzinga Insights
Baird Maintains Outperform on Apellis Pharmac...
Benzinga Newsdesk
Apellis shares are trading lower after the co...
Benzinga Newsdesk
Nike, Accolade And Other Big Stocks Moving Lower In Friday's Pre-Market Session
Avi Kapoor
Apellis Committee Says It Plans To Seek Re-ex...
Benzinga Newsdesk

Friday, May 31, 2024

Piper Sandler Initiates Coverage On Apellis P...
Benzinga Newsdesk

Tuesday, May 28, 2024

Expert Outlook: Apellis Pharmaceuticals Through The Eyes Of 15 Analysts
Benzinga Insights
HC Wainwright & Co. Reiterates Buy on Apellis...
Benzinga Newsdesk

Friday, May 24, 2024

Apellis Pharmaceuticals And Sobi Announce Pos...
Benzinga Newsdesk

Thursday, May 23, 2024

Wells Fargo Maintains Equal-Weight on Apellis...
Benzinga Newsdesk

Tuesday, May 14, 2024

Apellis Pharmaceuticals Refinances Existing D...
Benzinga Newsdesk

Wednesday, May 08, 2024

Citigroup Maintains Buy on Apellis Pharmaceut...
Benzinga Newsdesk
HC Wainwright & Co. Reiterates Buy on Apellis...
Benzinga Newsdesk
In-Depth Examination Of 14 Analyst Recommendations For Apellis Pharmaceuticals
Benzinga Insights
UBS Maintains Buy on Apellis Pharmaceuticals,...
Benzinga Newsdesk
Needham Reiterates Buy on Apellis Pharmaceuti...
Benzinga Newsdesk

Tuesday, May 07, 2024

Apellis Pharmaceuticals shares are trading lo...
Benzinga Newsdesk
Apellis Pharmaceuticals Q1 EPS $(0.54) Misses...
Benzinga Newsdesk

Tuesday, April 30, 2024

A Closer Look at Apellis Pharmaceuticals's Options Market Dynamics
Benzinga Insights

Monday, April 29, 2024

Mizuho Maintains Neutral on Apellis Pharmaceu...
Benzinga Newsdesk

Friday, April 26, 2024

HC Wainwright & Co. Reiterates Buy on Apellis...
Benzinga Newsdesk
Apellis Pharmaceuticals shares are trading hi...
Benzinga Newsdesk
European Medicines Agency Has Reset The Revie...
Benzinga Newsdesk

Thursday, April 25, 2024

Needham Reiterates Buy on Apellis Pharmaceuti...
Benzinga Newsdesk

Thursday, April 18, 2024

Behind the Scenes of Apellis Pharmaceuticals's Latest Options Trends
Benzinga Insights

Wednesday, April 17, 2024

Wedbush Maintains Neutral on Apellis Pharmace...
Benzinga Newsdesk

Monday, April 15, 2024

Expert Ratings For Apellis Pharmaceuticals
Benzinga Insights
HC Wainwright & Co. Reiterates Buy on Apellis...
Benzinga Newsdesk

Wednesday, April 10, 2024

If You Invested $1000 In This Stock 5 Years Ago, You Would Have $3,000 Today
Benzinga Insights

Tuesday, April 09, 2024

Needham Reiterates Buy on Apellis Pharmaceuti...
Benzinga Newsdesk

Friday, March 29, 2024

$1000 Invested In This Stock 5 Years Ago Would Be Worth $3,000 Today
Benzinga Insights

Wednesday, March 27, 2024

Decoding 15 Analyst Evaluations For Apellis Pharmaceuticals
Benzinga Insights
Mizuho Maintains Neutral on Apellis Pharmaceu...
Benzinga Newsdesk

Friday, March 15, 2024

Peering Into Apellis Pharmaceuticals's Recent Short Interest
Benzinga Insights

Wednesday, March 06, 2024

JP Morgan Maintains Overweight on Apellis Pha...
Benzinga Newsdesk

Monday, March 04, 2024

UBS Maintains Buy on Apellis Pharmaceuticals,...
Benzinga Newsdesk

Wednesday, February 28, 2024

Deep Dive Into Apellis Pharmaceuticals Stock: Analyst Perspectives (18 Ratings)
Benzinga Insights
HC Wainwright & Co. Reiterates Buy on Apellis...
Benzinga Newsdesk
ICU Medical To Rally Around 28%? Here Are 10 Top Analyst Forecasts For Wednesday
Avi Kapoor
Wedbush Maintains Neutral on Apellis Pharmace...
Benzinga Newsdesk

Tuesday, February 27, 2024

Apellis Pharmaceuticals Q4 EPS $(0.73) Misses...
Benzinga Newsdesk
Earnings Scheduled For February 27, 2024
Benzinga Insights

Thursday, February 22, 2024

Here's How Much You Would Have Made Owning Apellis Pharmaceuticals Stock In The Last 5 Years
Benzinga Insights

Friday, February 16, 2024

Mizuho Maintains Neutral on Apellis Pharmaceu...
Benzinga Newsdesk

Tuesday, February 06, 2024

Baird Reiterates Outperform on Apellis Pharma...
Benzinga Newsdesk

Monday, February 05, 2024

$1000 Invested In Apellis Pharmaceuticals 5 Years Ago Would Be Worth This Much Today
Benzinga Insights
Pinterest To Rally Over 20%? Here Are 10 Top Analyst Forecasts For Monday
Avi Kapoor
Jefferies Upgrades Apellis Pharmaceuticals to...
Benzinga Newsdesk

Tuesday, January 30, 2024

Critical Insights From Apellis Pharmaceuticals Analyst Ratings: What You Need To Know
Benzinga Insights
Oppenheimer Maintains Outperform on Apellis P...
Benzinga Newsdesk

Create a Watchlist

FREE: Follow your stocks and cryptocurrencies with the most actionable alerts on the internet.

People Also Watch

Popular Channels

PreMarket Prep
Press Releases
Analyst Ratings
News
Options
ETFs

Tools & Features

Real Time Feed
Public RSS Feeds
Submit News Tips
Blog
Embeddable Finance Widgets & Tools
Benzinga Catalyst

Partners & Contributors

Affiliate Program
Contributor Portal
Licensing & Syndication
Sponsored Content
Advertise With Us
Lead Generation & SEO

About Benzinga

About Us
Careers
In The News
Events
Contact Us

Terms & Conditions
Do Not Sell My Personal Data/Privacy Policy
Disclaimer
Service Status
Sitemap

© 2024 Benzinga | All Rights Reserved